Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Fig. FACS analysis of Transferrin R on HEK293/Human Transferrin R Stable Cell Line.
FACS assay shows that Anti-Transferrin Receptor antibody can bind to HEK293/Human Transferrin R Stable Cell Line. HEK293/Human Transferrin R Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Human Transferrin R Protein, Fc Tag (Cat. No. TFR-H5264) captured on Protein A Chip can bind Human Transferrin, His Tag with an affinity constant of 0.491 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Immobilized Biotinylated Mouse Transferrin R Protein, His,Avitag (Cat. No. TFR-M82E3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Mouse Transferrin Protein, Mouse IgG2a Fc Tag (Cat. No. TRN-M525b) with a linear range of 0.2-6 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Pabinafusp alfa | JR-141 | Approved | Jcr Pharmaceuticals Co Ltd | Japan | Mucopolysaccharidosis II | Jcr Pharmaceuticals Co Ltd | 2021-03-23 | Mucopolysaccharidosis II | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Human apotransferrin (Sanquin Blood Supply Foundation) | Phase 3 Clinical | Sanquin Plasma Products Bv | Iron Metabolism Disorders; beta-Thalassemia | Details | |
| CX-2029 | ABBV-2029; ABBV-CX-2029; CX-2029 | Phase 2 Clinical | Abbvie Inc, Cytomx Therapeutics Inc | Head and Neck Neoplasms; Solid tumours; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
| DYNE-251 | DYNE251 | Phase 2 Clinical | Dyne Therapeutics Inc | Muscular Dystrophy, Duchenne | Details |
| Lepunafusp alfa | JR-171 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis I | Details |
| PPMX-T003 | PPMX-T003 | Phase 2 Clinical | Perseus Proteomics Inc | Leukemia; Polycythemia Vera | Details |
| Delpacibart eteddesiran | AOC-1001 | Phase 2 Clinical | Avidity Biosciences Inc | Myotonic Disorders; Genetic Diseases, Inborn; Musculoskeletal Diseases; Muscular Disorders, Atrophic; Myotonic Dystrophy; Muscular Atrophy; Muscular Diseases; Heredodegenerative Disorders, Nervous System; Neuromuscular Diseases; Nervous System Diseases; Muscular Dystrophies; Neurodegenerative Diseases | Details |
| Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
| INA-03 | INA03 | Phase 1 Clinical | Inatherys | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| ABX-1100 | ABX-1100 | Phase 1 Clinical | Aro Biotherapeutics Co | Glycogen Storage Disease Type II | Details |
This web search service is supported by Google Inc.
A-Z
